Last reviewed · How we verify
NCT03538275
Chronobiology and Depression: Circadian Analytics as a Biomarker for Depressive Subtypes
trial testing Monitoring test in Depression, Bipolar in 80 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | Medibio Limited |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 13 March 2018 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Monitoring test
Conditions studied
- Depression, Bipolar — all drugs for Depression, Bipolar →
- Depression, Unipolar — all drugs for Depression, Unipolar →
- Healthy — all drugs for Healthy →
Sponsor
Medibio Limited
Who can join
Adults 18 to 75, any sex, with Depression, Bipolar or Depression, Unipolar. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An objective measure of treatment response could be a valuable new tool in the armamentarium of depression management, and this holds true for stimulation-based and pharmacological therapies alike. Hence, the Medibio Depression Monitoring Study will use the Medibio analytics platform to characterize autonomic, circadian, and sleep patterns before and during the initial 8 weeks of pharmacologic therapy for moderate-to-severe depression. The study will also explore any differences in these measures between treatment responders and non-responders, and between depression subtypes, including bipolar and unipolar depression. The study will also characterize longitudinal, ambulatory EEG measures throughout the observation period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03538275
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Depression, Bipolar
Currently open trials in the same condition.
- NCT06462196 — Natural History of Depression, Bipolar Disorder and Suicide Risk · recruiting
- NCT05913947 — Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9) · Phase 4 · recruiting
- NCT05767073 — LIVES: Personalized Lifestyle Intervention for Patients With Depression · NA · recruiting
- NCT04057378 — Optimal Electrical Stimulus During Electroconvulsive Therapy · Phase 4 · recruiting
Other Medibio Limited trials
Trials by the same sponsor.
- NCT05708222 — Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) · completed
- NCT04232267 — Analysis of Sleep Study Data to Assess Depressive Burden · completed
- NCT03529513 — Medibio DDA Confirmatory Performance Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03538275 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medibio Limited
- Last refreshed: 26 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03538275.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing